This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Christopher Voigt | |
|---|---|
| Name | Christopher Voigt |
| Nationality | American |
| Fields | Synthetic biology, Genetic engineering, Systems biology |
| Institutions | Massachusetts Institute of Technology, Broad Institute, Wyss Institute for Biologically Inspired Engineering, University of California, San Francisco |
| Alma mater | University of Oregon, Massachusetts Institute of Technology |
| Doctoral advisor | Adam Arkin |
| Known for | Synthetic biology, Genetic circuits, CRISPR |
Christopher Voigt is an American scientist and engineer known for contributions to synthetic biology, genetic engineering, and the design of programmable biological systems. He has led research that integrates principles from electrical engineering and computer science into engineering of microbial genomes, regulatory networks, and biosensors. His work spans academic institutions, biotechnology startups, and collaborations with national laboratories and international consortia.
Voigt completed undergraduate studies at the University of Oregon and received a Ph.D. from the Massachusetts Institute of Technology under the supervision of Adam Arkin. During his training he engaged with groups at the Whitehead Institute, the Broad Institute, and the Wyss Institute for Biologically Inspired Engineering that intersected with research programs led by investigators from Harvard University, Stanford University, and the University of California, San Diego. His doctoral and postdoctoral period overlapped scientifically with researchers affiliated with the National Institutes of Health, the Howard Hughes Medical Institute, and the Alfred P. Sloan Foundation-supported initiatives.
Voigt has held faculty positions and leadership roles that connected Massachusetts Institute of Technology-affiliated labs to translational efforts involving the Industrial Biotechnology sector, collaborations with the Department of Energy, and partnerships with companies from Cambridge, Massachusetts and San Francisco. His laboratory developed modular platforms for constructing genetic circuits in Escherichia coli, Saccharomyces cerevisiae, and nonmodel microorganisms relevant to biofuel and bioproduct synthesis. The group has collaborated with teams at the Broad Institute, the Wyss Institute, MIT Media Lab, and the Koch Institute for Integrative Cancer Research to adapt tools such as CRISPR/Cas9, TALENs, and engineered transcription factors for programmable control. Voigt’s career includes interactions with companies and organizations such as Amyris, Ginkgo Bioworks, Zymergen, Intrexon, Genentech, Novartis, Pfizer, Eli Lilly and Company, and government labs including Oak Ridge National Laboratory and the Lawrence Berkeley National Laboratory.
Voigt’s laboratory advanced the design-build-test-learn cycle central to contemporary synthetic biology by creating libraries of orthogonal regulatory parts, standardized measurement frameworks, and circuit design strategies that enabled predictable behavior across chassis such as E. coli, Bacillus subtilis, and engineered yeast. Notable innovations include synthetic transcriptional regulators, programmable genetic logic gates, biosensors for small molecules and environmental signals, and metabolic pathway refactoring for production of fuels and chemicals. These advances interfaced with technologies like next-generation sequencing, mass spectrometry, microfluidics, and high-throughput screening used across institutions such as Lawrence Livermore National Laboratory, Sandia National Laboratories, and Argonne National Laboratory. His work influenced efforts in gene therapy research, vaccine platform development with stakeholders including Moderna, BioNTech, and Johnson & Johnson, and contributed to standards initiatives alongside the International Genetically Engineered Machine Competition, the BioBricks Foundation, and agencies such as the National Science Foundation and the Defense Advanced Research Projects Agency.
Voigt’s recognition includes prizes, fellowships, and invited lectures from organizations such as the National Institutes of Health, the National Science Foundation, the Burroughs Wellcome Fund, and professional societies including the American Association for the Advancement of Science and the American Chemical Society. He has delivered keynote addresses at conferences organized by Gordon Research Conferences, Cold Spring Harbor Laboratory, and the International Conference on Synthetic Biology (SB) series, and held visiting appointments at institutions like Harvard University, Stanford University, ETH Zurich, Max Planck Society institutes, and the University of Cambridge.
Representative publications and patents associated with Voigt cover topics in genetic circuit design, metabolic engineering, biosensor development, and genome editing. His authored and coauthored works have appeared in journals and proceedings including Nature, Science, Cell, Nature Biotechnology, Nature Communications, PNAS, ACS Synthetic Biology, Cell Systems, Molecular Systems Biology, Genome Research, and conference collections from IEEE. He is listed as inventor on patents concerning engineered regulatory proteins, tunable genetic elements, and platform technologies for strain optimization that have been assigned to universities and biotechnology companies working with organizations such as DARPA and the Bill & Melinda Gates Foundation.
Category:Synthetic biologists Category:American bioengineers